ClinicalTrials.gg
Not yet recruitingNCT07603557Updated Jul 9, 2026

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

A Phase 2 interventional study of BMS-986353 and Fludarabine Phosphate in Chronic Immune Thrombocytopenia and Autoimmune Hemolytic Anemia, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Not yet recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Planned enrollment
6th of 30
52 · median 24
Started
2026
the only one that year
Phase 2
14 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 6th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2026, is one of 14 in phase 2, and was the 31st registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).

03

Conditions studied

  • Chronic Immune Thrombocytopenia
  • Autoimmune Hemolytic Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

Inclusion Criteria for ITP

  • Documented clinical diagnosis of chronic ITP (cITP) without other clinical manifestations of systemic disease.
  • Has after or is intolerant to (with or without intravenous immunoglobulin (IVIG) or anti-Rh0(D) Ig) AND has failed, relapsed after, or is intolerant to therapies with ≥ 2 mechanisms of action, with at least one being or immunomodulatory.

count \< 30 × 109/L. For participants on thrombopoietin receptor agonist (TPO-RA): platelet count \< 50 × 109/L.

Inclusion Criteria for AIHA

  • Documented clinical diagnosis of AIHA (including warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), or mixed AIHA) without other clinical manifestations of systemic autoimmune disease.

    o wAIHA and mixed warm and cold AIHA: Failed, relapsed after, or is intolerant to at least 2 with 2 mechanisms of action (not including corticosteroids or IVIG), one of which is an anti-CD20 monoclonal antibody unless there is a documented .

    o CAD (all of the following must apply): Failed, relapsed after, or is intolerant to at least 2 prior lines of treatment with 2 mechanisms of action, one of which is an anti-CD20 monoclonal antibody with or without chemotherapy unless there is a documented contraindication.

  • \<10 g/dL without red blood cell transfusion, or transfusion dependent
  • Documented hemolysis

Exclusion Criteria

Medical Conditions

  • ITP or AIHA associated with: Evans syndrome, other systemic autoimmune disease or single organ autoimmune disease requiring systemic immunosuppressive therapy, virus, , drug induced (eg, non-steroidal anti-inflammatory drug (NSAIDS), trimethoprim/sulfamethoxazole (TMP-SMX), anticonvulsants), surgical procedures, or hematologic .
  • COVID-19 Vaccine-induced immune thrombotic thrombocytopenia
  • Prior history of solid organ malignancies, unless the participant has been free of the disease for ≥ 2 years.

Laboratory Test Findings

  • Peripheral blood ANC \< 1.5 × 109/L or requiring G-CSF or GM-CSF support o /AST: ITP: ALT/AST: > 3 × AIHA: ALT > 3 ULN. AST up to 5 × ULN may be permitted. o : ITP: total bilirubin > 1.5 × ULN AIHA: direct bilirubin > 1.5 × ULN o (INR) > 1.5 × ULN

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Part A ITP

    Biological: BMS-986353 · Drug: Fludarabine Phosphate · Drug: Cyclophosphamide

  • Experimental
    Cohort 1 Part A AIHA

    Biological: BMS-986353 · Drug: Fludarabine Phosphate · Drug: Cyclophosphamide

  • Experimental
    Cohort 1 Part B

    Biological: BMS-986353 · Drug: Fludarabine Phosphate · Drug: Cyclophosphamide

  • Experimental
    Cohort 2

    Biological: BMS-986353 · Drug: Fludarabine Phosphate · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to approximately Month 36

  2. Cohort 1 Part A: Number of participants with serious AEs (SAEs)

    Time frame: Up to approximately Month 36

  3. Cohort 1 Part A: Number of participants with AEs of special interest (AESI)

    Time frame: Up to approximately Month 36

  4. Cohort 1 Part A: Number of participants with clinically significant laboratory abnormalities

    Time frame: Up to approximately Month 36

  5. Cohort 1 Part B: Hematologic Complete Response (CR)

    Time frame: Up to approximately Month 6

Secondary outcomes

  1. Cohort 1 PART B: Hematologic Overall Response (OR)

    Time frame: Up to approximately Month 6

  2. Cohort 1 PART A and Cohort 2: Hematologic CR and OR

    Time frame: Up to approximately Month 6

  3. Cohort 1 PART B and Cohort 2: Number of participants with TEAEs

    Time frame: Up to approximately Month 36

  4. Cohort 1 PART B and Cohort 2: Number of participants with SAEs

    Time frame: Up to approximately Month 36

  5. Cohort 1 PART B and Cohort 2: Number of participants with AESIs

    Time frame: Up to approximately Month 36

  6. Cohort 1 PART B and Cohort 2: Number of participants with clinically significant laboratory abnormalities

    Time frame: Up to approximately Month 36

  7. Number of participants with Hematologic PR

    Time frame: Up to approximately Month 6

  8. Number of participants with Hematologic CR

    Time frame: Up to approximately Month 36

  9. Number of participants with Hematologic PR

    Time frame: Up to approximately Month 36

  10. Number of participants with Hematologic OR

    Time frame: Up to approximately Month 36

  11. Number of participants with Best Overall Response (BOR)

    Time frame: Up to approximately Month 36

  12. Number of participants with durable CR, PR and OR

    Time frame: Up to approximately 12 months from Zola-cel infusion

  13. Time to First Response (TTR)

    Time frame: Up to approximately Month 36

  14. Time to First Complete Response (TTCR)

    Time frame: Up to approximately Month 36

  15. Duration of response (DOR)

    Time frame: Up to approximately Month 36

  16. Treatment-free Remission (TFR)

    Time frame: Up to approximately Month 36

  17. Proportion of participants who requires rescue therapy for ITP or AIHA

    Time frame: Up to approximately Month 36

  18. Time to first administration of rescue therapy for ITP or AIHA

    Time frame: Up to approximately Month 36

  19. Proportion of AIHA participants who experience hemolysis features

    Time frame: Up to approximately Month 36

  20. Number of AIHA participants with cold agglutinin disease (CAD) who experience acrocyanosis

    Time frame: Up to approximately Month 36

  21. Change from baseline in hemolysis indicators in AIHA participants

    Time frame: Up to approximately Month 36

  22. Proportion of ITP participants with WHO-classified bleeding events as assessed by WHO bleeding scale

    Time frame: Up to approximately Month 36

  23. Change from baseline in 36-Item Short Form Health Questionnaire version 2 (SF-36 v2)

    Time frame: Up to approximately Month 36

  24. Change from baseline in Patient Global Impression of Severity (PGI-S) Fatigue score

    Time frame: Up to approximately Month 36

  25. Patient Global Impression of Change (PGI-C) Fatigue mean score

    Time frame: Up to approximately Month 36

  26. Change from baseline in Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP - PAQ) score

    Time frame: Up to approximately Month 36

  27. Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score

    Time frame: Up to approximately Month 36

07

Study locations

8 sites
  • Local Institution - 101
    Boston, Massachusetts 02114, United States
    • Site 101 · Contact
  • Local Institution - 103
    Houston, Texas 77030-2740, United States
    • Site 103 · Contact
  • Local Institution - 102
    Seattle, Washington 98109, United States
    • Site 102 · Contact
  • Local Institution - 201
    Odense, DK-5000, Denmark
    • Site 201 · Contact
  • Local Institution - 301
    Magdeburg, Saxony-Anhalt 39120, Germany
    • Site 301 · Contact
  • Local Institution - 302
    Erlangen, 91054, Germany
    • Site 302 · Contact
  • Local Institution - 401
    London, Greater London W12 OHS, United Kingdom
    • Site 401 · Contact
  • Local Institution - 402
    Sheffield, S10 2SJ, United Kingdom
    • Site 402 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for May 2030, 44 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
May 6, 2030
CompletionEst.
May 6, 2030
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07603557
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
May 6, 2030 (estimated)
Completion
May 6, 2030 (estimated)
Last update
Jul 9, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolacabtagene autoleucel

Start the discussion